Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941.

Authors

D E Furst¹, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, P J Mease

Affiliation

¹ 1000 Veteran Avenue Rehabilitation Centre, Room 32-59, Los Angeles, CA 90024, USA. [email protected]

No abstract available

Publication types

Consensus Development Conference
Review

MeSH terms

Antirheumatic Agents / adverse effects
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy
Evidence-Based Medicine
Humans
Interleukin 1 Receptor Antagonist Protein
Rheumatic Diseases / drug therapy*
Sialoglycoproteins / antagonists & inhibitors*
Spondylitis, Ankylosing / drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antirheumatic Agents
IL1RN protein, human
Interleukin 1 Receptor Antagonist Protein
Sialoglycoproteins
Tumor Necrosis Factor-alpha